Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids

Stewart EA, Laughlin-Tommaso SK, Catherino WH, et al. Uterine fibroids. Nat Rev Dis Prim. 2016;2:16043.

Article  PubMed  Google Scholar 

Bulun SE. Uterine fibroids. N Engl J Med. 2013;369(14):1344–55.

Article  CAS  PubMed  Google Scholar 

Stewart EA, Cookson CL, Gandolfo RA, et al. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501–12.

Article  CAS  PubMed  Google Scholar 

Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293–8.

Article  CAS  PubMed  Google Scholar 

Al-Hendy A, Myers ER, Stewart E. Uterine fibroids: burden and unmet medical need. Semin Reprod Med. 2017;35(6):473–80.

Article  PubMed  PubMed Central  Google Scholar 

U.S. Food and Drug Administration. Myfembree: clinical review (NDA 214846). 2021. https://www.accessdata.fda.gov/. Accessed 21 Sept 2022.

European Medicines Agency. Ryeqo: Committee for Medicinal Products for Human Use assessment report. 2021. https://www.ema.europa.eu/en/documents/assessment-report/ryeqo-epar-public-assessment-report_en.pdf. Accessed 21 Sept 2022.

Perez-Lopez FR, Ornat L, Ceausu I, et al. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79(1):106–16.

Article  PubMed  Google Scholar 

Al-Hendy A, Lukes AS, Poindexter AN III, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384(7):630–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328–40.

Article  CAS  PubMed  Google Scholar 

Myovant Sciences Inc. Myfembree® (relugolix, estradiol, and norethindrone acetate) tablets, for oral use: US prescribing information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214846s000lbl.pdf. Accessed 21 Sept 2022.

European Medicines Agency. Ryeqo 40 mg/1 mg/0.5 mg film-coated tablets: EU summary of product characteristics. 2022. https://www.ema.europa.eu/en/documents/product-information/ryeqo-epar-product-information_en.pdf. Accessed 21 Sept 2022.

Miwa K, Hitaka T, Imada T, et al. Discovery of 1--3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2011;54(14):4998–5012.

Article  CAS  PubMed  Google Scholar 

Nakata D, Masaki T, Tanaka A, et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014;723:167–74.

Article  CAS  PubMed  Google Scholar 

Delmas PD, Confavreux E, Garnero P, et al. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int. 2000;11(2):177–87.

Article  CAS  PubMed  Google Scholar 

Kurman RJ, Felix JC, Archer DF, et al. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol. 2000;96(3):373–9.

CAS  PubMed  Google Scholar 

Hoshiai H, Seki Y, Kusumoto T, et al. Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial. BMC Womens Health. 2021;21(1):375.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Osuga Y, Enya K, Kudou K, et al. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019;133(3):423–33.

Article  CAS  PubMed  Google Scholar 

Osuga Y, Enya K, Kudou K, et al. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril. 2019;112(5):922-9.e2.

Article  CAS  PubMed  Google Scholar 

Lukes A, Johnson B, Jones L, et al. Pharmacokinetics, pharmacodynamics, and safety of relugolix, a potent oral once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist, as monotherapy and in combination with estradiol/norethindrone acetate add-back therapy [abstract]. Hum Reprod. 2017;32:i267–8.

Google Scholar 

Duijkers I, Klipping C, Draeger C, et al. Suppression of ovarian activity during co-administration of the oral gonadotropin-releasing hormone receptor antagonist relugolix, estradiol, and norethindrone acetate in healthy female volunteers [abstract no. P-287]. Hum Reprod. 2020;35(Suppl 1).

Al-Hendy A, Lukes AS, Poindexter A, et al. LIBERTY: Long-term extension study demonstrating one-year efficacy and safety of relugolix combination therapy in women with symptomatic uterine fibroids [abstract no. O-1]. Fertil Steril. 2020;114(Suppl 3):e1.

Venturella R, Al-Hendy A, Nyirady T, et al. Relugolix combination therapy in European women with symptomatic uterine fibroids in the liberty long-term extension (LTE) study [abstract no. 69]. Eur J Obstet Gynecol Reprod Biol. 2022;270:e32.

Al-Hendy A, Venturella R, Arjona Ferreira JC, et al. Liberty randomized withdrawal study: 2-year efficacy and safety of relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids [abstract no. O-5]. Fertil Steril. 2021;116(Suppl 3):e2.

McClung MR, Santora A, Al-Hendy A, et al. Evaluation of relugolix combination therapy to maintain bone mass in women with uterine fibroids through 52 weeks: LIBERTY long-term extension study [abstract no. P-639]. J Bone Miner Res. 2020;35(Suppl 1):245–6.

McClung MR, Lukes AS, Venturella R, et al. Effects of relugolix combination therapy on bone mineral density through 2 years in women with heavy menstrual bleeding associated with uterine fibroids [abstract no. O-30]. Fertil Steril. 2021;116(Suppl 3):e13.

McClung MR, Santora A, Al-Hendy A, et al. A prospective observational study of bone mineral density in premenopausal women with uterine fibroids [abstract no. P-552]. J Bone Miner Res. 2020;35(Suppl 1):220.

AbbVie Inc. Oriahnn® (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), co-packaged for oral use: US prescribing information. 2020. https://www.oriahnn.com/. Accessed 21 Sept 2022.

European Medicines Agency. Esmya 5 mg tablets: EU summary of product characteristics. 2012. https://www.ema.europa.eu/en/documents/product-information/ryeqo-epar-product-information_en.pdf. Accessed 21 Sept 2022.

Hunsche E, Rakov V, Scippa K, et al. The burden of uterine fibroids from the perspective of US women participating in open-ended interviews. Womens Health Rep (New Rochelle). 2022;3(1):286–96.

PubMed  PubMed Central  Google Scholar 

Hartmann KE, Fonnesbeck C, Surawicz T, et al. Management of uterine fibroids. Comparative effectiveness review no. 195. AHRQ Publication No 17(18)-EHC028-EF. 2017. https://doi.org/10.23970/AHRQEPCCER195.

Amoah A, Joseph N, Reap S, et al. Appraisal of national and international uterine fibroid management guidelines: a systematic review. BJOG. 2022;129(3):356–64.

Article  CAS  PubMed  Google Scholar 

National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management: NICE guideline [NG88]. 2018. https://www.nice.org.uk/. Accessed 21 Sept 2022.

留言 (0)

沒有登入
gif